🇺🇸 FDA
Patent

US 10100310

Modulation of prekallikrein (PKK) expression

granted A61KA61K31/7088A61K38/36

Quick answer

US patent 10100310 (Modulation of prekallikrein (PKK) expression) held by Ionis Pharmaceuticals, Inc. expires Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Oct 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/7088, A61K38/36, A61P, A61P29/00